India to Russia: Acyclovir Export Trade Route

To import finished pharmaceutical formulations containing Acyclovir into Russia, compliance with the Federal Law No. 61-FZ "On the Circulation of Medicines" dated April 12, 2010, is mandatory. This law mandates that all medicinal products, including finished dosage forms, undergo state registration with Roszdravnadzor before they can be manufactured, sold, or imported into the Russian Federation.

Registration Process:

1. Dossier Submission: Applicants must prepare a comprehensive registration dossier in the Common Technical Document (CTD) format, encompassing quality, safety, and efficacy data.

2. Expert Review: Roszdravnadzor conducts an expert evaluation of the submitted dossier, which includes document review, production process assessment, and sampling for quality control tests.

3. Clinical Trials: If deemed necessary, clinical trials may be required to substantiate the product's safety and efficacy.

Timelines:

The standard registration process is stipulated to take 210 working days, excluding the duration required for clinical trials.

Fees:

The registration process involves state fees for the expert review of documentation quality and the issuance of the registration certificate. Additionally, costs for laboratory testing, translation, and notarization services may apply.

GMP Inspection Requirements:

Indian manufacturing facilities producing Acyclovir formulations intended for the Russian market must comply with Good Manufacturing Practice (GMP) standards. Roszdravnadzor requires a GMP certificate issued by the Russian authorities, confirming that the manufacturing site adheres to the established GMP requirements. This certification process involves an inspection of the manufacturing facility to ensure compliance.

Indian exporters of Acyclovir formulations must obtain GMP certification from the Russian authorities to supply products to Russia. This certification verifies that the manufacturing facilities comply with the GMP standards as per Russian regulations.

Approved Facilities:

As of March 2026, specific details regarding Indian facilities currently approved by Roszdravnadzor for Acyclovir formulations are not publicly disclosed.

Recent Inspections and Regulatory Actions:

In March 2025, the Russian Ministry of Health proposed amendments to the rules for introducing medicines into circulation. Starting from September 2024, manufacturers are required to confirm the quality of each batch of pharmaceutical substances with Roszdravnadzor. This new regulation affects both finished dosage forms and pharmaceutical substances. Applicants must submit the requested drug samples and related documentation within 90 business days from the date of the request. Previously, this period was 30 working days. If delays occur due to the need to purchase or import samples for quality control methods, applicants must submit a corresponding application with the necessary documents.

Between 2024 and 2026, several regulatory changes have impacted Indian pharmaceutical exports to Russia:

1. Amendments to Medicine Circulation Rules: In March 2025, the Russian Ministry of Health introduced amendments requiring manufacturers to confirm the quality of each batch of pharmaceutical substances with Roszdravnadzor, effective from September 2024. This change extends to both finished dosage forms and pharmaceutical substances, with an extended submission period of 90 business days for required samples and documentation.

2. GMP Certification Requirements: Since 2016, Russian regulations mandate that foreign manufacturers, including those from India, obtain GMP certification from Russian authorities for their manufacturing facilities. This certification is essential for the registration and importation of pharmaceutical products into Russia.

These developments underscore the importance for Indian exporters to stay informed about Russian regulatory requirements and ensure compliance to maintain market access.

As of 2025, the Russian market for Acyclovir formulations is valued at approximately $125 million USD. This demand is primarily driven by the prevalence of herpes simplex virus (HSV) infections, which affect a significant portion of the population. The aging demographic and increased healthcare spending have further contributed to the consistent demand for antiviral medications like Acyclovir. Russia maintains a balance between domestic production and imports to meet this demand. While local pharmaceutical companies manufacture a substantial portion of Acyclovir formulations, imports, particularly from countries like India, play a crucial role in supplementing domestic supply and ensuring a steady availability of the drug.

Pharmaceutical imports under HS code 30049099 into Russia are subject to a 0% import duty, aligning with the country's policy to facilitate access to essential medicines. Additionally, these imports are subject to a Value-Added Tax (VAT) of 10%, which is the standard rate for pharmaceutical products in Russia. There are no Free Trade Agreements (FTAs) between India and Russia that specifically affect pharmaceutical tariffs. Furthermore, there are no anti-dumping duties imposed on Acyclovir formulations imported from India, indicating a stable trade relationship in this sector.

India is a significant supplier of Acyclovir formulations to Russia, accounting for approximately 1.2% of India's total Acyclovir formulation exports, valued at $1.5 million USD. Other major countries supplying Acyclovir to Russia include China and various European Union (EU) member states. India's share of Russia's total Acyclovir imports is substantial, reflecting the strong trade ties between the two nations in the pharmaceutical sector. In terms of pricing, Indian Acyclovir formulations are competitively priced compared to those from China and EU manufacturers. This cost-effectiveness, combined with adherence to international quality standards, positions Indian pharmaceutical companies favorably in the Russian market.

India is a global leader in generic pharmaceutical production, accounting for approximately 20% of the global supply by volume as of 2024. The country's extensive manufacturing infrastructure includes numerous facilities dedicated to producing finished dosage forms containing Acyclovir, such as tablets, capsules, and syrups. This scale enables cost efficiencies, allowing Indian manufacturers to offer competitive pricing without compromising quality. As of 2025, India boasts 396 FDA-approved facilities, underscoring its commitment to maintaining high manufacturing standards. Additionally, many Indian plants hold WHO-GMP certifications, ensuring compliance with international quality benchmarks. For instance, Granules India Limited's Hyderabad facility received U.S. FDA approval in November 2025, marking a significant milestone in expanding its finished dosage manufacturing capabilities.

When comparing Acyclovir formulation exports, India offers a compelling balance of cost and quality. Generic formulations from China may present lower initial costs; however, concerns regarding quality perception and regulatory acceptance can pose challenges in markets like Russia. The European Union (EU) provides branded generics known for high quality but at a premium price point. Local Russian manufacturers offer proximity advantages but may lack the production scale and cost efficiencies of Indian counterparts. As of December 31, 2024, the average unit price for generic oral solids in India was $0.13, compared to $0.19 in the United States and $0.12 in China. Indian pharmaceutical products are widely accepted in Russia, with a strong track record of regulatory compliance and supply reliability.

The India-Russia supply chain for Acyclovir formulations is robust, supported by India's substantial manufacturing capacity and advanced packaging and cold chain logistics. Indian manufacturers have demonstrated a consistent track record of regulatory compliance, with facilities regularly inspected and approved by international agencies, including the U.S. FDA and WHO. For example, in May 2024, Dr. Reddy's Laboratories' formulations manufacturing facilities in Visakhapatnam underwent a routine GMP inspection by the U.S. FDA, resulting in a Voluntary Action Indicated (VAI) classification, indicating satisfactory compliance. While no significant supply disruptions have been reported recently, ongoing modernization and capacity expansion efforts, such as those at Granules India's facilities, ensure the ability to meet increasing demand.

• Implement a Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions and ensure a consistent supply of Acyclovir formulations.

• Understand Minimum Order Quantities (MOQs): Indian suppliers typically require MOQs ranging from 100,000 to 500,000 units per order, depending on the formulation and packaging specifications.

• Negotiate Favorable Payment Terms: Common payment terms in India-Russia pharmaceutical trade include a 30% advance payment with the balance payable upon delivery or through a letter of credit.

• Conduct Thorough Supplier Qualification: Evaluate potential suppliers based on their regulatory approvals (e.g., FDA, WHO-GMP), manufacturing capacity, quality control systems, and track record of supply reliability.

• Stay Informed on Regulatory Changes: Regularly monitor both Indian and Russian regulatory environments to ensure compliance and adapt sourcing strategies accordingly.

Cost Estimates and Timeline:

• Audit Visits to India:
• Cost: Approximately $10,000 to $15,000 USD per audit, covering travel, accommodation, and professional fees.
• Timeline: Planning and coordination may take 4-6 weeks, with the on-site audit lasting 3-5 days, followed by a report issuance within 2 weeks.

By adhering to this comprehensive supplier qualification process, Russian pharmaceutical companies can ensure the quality, safety, and regulatory compliance of Acyclovir formulations sourced from Indian manufacturers.